1
|
Jansen A, Bruse N, Waalders N, Gerretsen J, Rijbroek D, Pickkers P, Kox M. Ex vivo and in vitro Monocyte Responses Do Not Reflect in vivo Immune Responses and Tolerance. J Innate Immun 2022; 15:174-187. [PMID: 35940121 PMCID: PMC10643897 DOI: 10.1159/000525572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Accepted: 06/16/2022] [Indexed: 11/19/2022] Open
Abstract
Cytokine production by ex vivo (EV)-stimulated leukocytes is commonly used to gauge immune function and frequently proposed to guide immunomodulatory therapy. However, whether EV cytokine production capacity accurately reflects the in vivo (IV) immune status is largely unknown. We investigated relationships between EV monocyte cytokine responses and IV cytokine responses in a large cohort of healthy volunteers using a highly standardized IV model of short-lived LPS-induced systemic inflammation, which captures hallmarks of both hyperinflammation and immunological tolerance. Therefore, 110 healthy volunteers were intravenously challenged with 1 ng/kg LPS twice: on day 0 to determine the extent of the IV (hyper)inflammatory response and on day 7 to determine the degree of IV endotoxin tolerance. Baseline EV monocyte cytokine production capacity was assessed prior to LPS administration. Short-term and long-term EV tolerance was assessed in monocytes isolated 4 h and 7 days after LPS administration, respectively. No robust correlations were observed between baseline EV cytokine production capacity and IV cytokine responses following LPS administration. However, highly robust inverse correlations were observed between IV cytokine responses and EV cytokine responses of monocytes isolated 4 h after IV LPS administration. No correlations between IV and EV tolerance were found. In conclusion, attenuated EV cytokine production capacity reflects ongoing IV inflammation rather than immune suppression. Results of EV assays should be interpreted with caution at the risk of improper use of immuno-stimulatory drugs.
Collapse
Affiliation(s)
- Aron Jansen
- Department of Intensive Care Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands
- Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands
| | - Niklas Bruse
- Department of Intensive Care Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands
- Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands
| | - Nicole Waalders
- Department of Intensive Care Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands
- Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands
| | - Jelle Gerretsen
- Department of Intensive Care Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands
- Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands
| | - Daniëlle Rijbroek
- Department of Intensive Care Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands
- Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands
| | - Peter Pickkers
- Department of Intensive Care Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands
- Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands
| | - Matthijs Kox
- Department of Intensive Care Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands
- Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
2
|
Pavlicevic M, Marmiroli N, Maestri E. Immunomodulatory peptides-A promising source for novel functional food production and drug discovery. Peptides 2022; 148:170696. [PMID: 34856531 DOI: 10.1016/j.peptides.2021.170696] [Citation(s) in RCA: 29] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Revised: 11/03/2021] [Accepted: 11/14/2021] [Indexed: 12/12/2022]
Abstract
Immunomodulatory peptides are a complex class of bioactive peptides that encompasses substances with different mechanisms of action. Immunomodulatory peptides could also be used in vaccines as adjuvants which would be extremely desirable, especially in response to pandemics. Thus, immunomodulatory peptides in food of plant origin could be regarded both as valuable suplements of novel functional food preparation and/or as precursors or possible active ingredients for drugs design for treatment variety of conditions arising from impaired function of immune system. Given variety of mechanisms, different tests are required to assess effects of immunomodulatory peptides. Some of those effects show good correlation with in vivo results but others, less so. Certain plant peptides, such as defensins, show both immunomodulatory and antimicrobial effect, which makes them interesting candidates for preparation of functional food and feed, as well as templates for design of synthetic peptides.
Collapse
Affiliation(s)
- Milica Pavlicevic
- Institute for Food Technology and Biochemistry, Faculty of Agriculture, University of Belgrade, Serbia
| | - Nelson Marmiroli
- University of Parma, Department of Chemistry, Life Sciences and Environmental Sustainability, and Interdepartmental Center SITEIA.PARMA, Parco Area delle Scienze 11/A, 43124 Parma, Italy
| | - Elena Maestri
- University of Parma, Department of Chemistry, Life Sciences and Environmental Sustainability, and Interdepartmental Center SITEIA.PARMA, Parco Area delle Scienze 11/A, 43124 Parma, Italy.
| |
Collapse
|
3
|
Shultz LD, Keck J, Burzenski L, Jangalwe S, Vaidya S, Greiner DL, Brehm MA. Humanized mouse models of immunological diseases and precision medicine. Mamm Genome 2019; 30:123-142. [PMID: 30847553 PMCID: PMC6610695 DOI: 10.1007/s00335-019-09796-2] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Accepted: 03/02/2019] [Indexed: 12/25/2022]
Abstract
With the increase in knowledge resulting from the sequencing of the human genome, the genetic basis for the underlying differences in individuals, their diseases, and how they respond to therapies is starting to be understood. This has formed the foundation for the era of precision medicine in many human diseases that is beginning to be implemented in the clinic, particularly in cancer. However, preclinical testing of therapeutic approaches based on individual biology will need to be validated in animal models prior to translation into patients. Although animal models, particularly murine models, have provided significant information on the basic biology underlying immune responses in various diseases and the response to therapy, murine and human immune systems differ markedly. These fundamental differences may be the underlying reason why many of the positive therapeutic responses observed in mice have not translated directly into the clinic. There is a critical need for preclinical animal models in which human immune responses can be investigated. For this, many investigators are using humanized mice, i.e., immunodeficient mice engrafted with functional human cells, tissues, and immune systems. We will briefly review the history of humanized mice, the remaining limitations, approaches to overcome them and how humanized mouse models are being used as a preclinical bridge in precision medicine for evaluation of human therapies prior to their implementation in the clinic.
Collapse
Affiliation(s)
- Leonard D Shultz
- The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, 04609, USA.
| | - James Keck
- The Jackson Laboratory, 1650 Santa Ana Avenue, Sacramento, CA, 95838, USA
| | - Lisa Burzenski
- The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, 04609, USA
| | - Sonal Jangalwe
- Diabetes Center of Excellence, The University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA, 01605, USA
| | - Shantashri Vaidya
- Diabetes Center of Excellence, The University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA, 01605, USA
| | - Dale L Greiner
- Diabetes Center of Excellence, The University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA, 01605, USA
| | - Michael A Brehm
- Diabetes Center of Excellence, The University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA, 01605, USA
| |
Collapse
|
4
|
Maestri E, Pavlicevic M, Montorsi M, Marmiroli N. Meta-Analysis for Correlating Structure of Bioactive Peptides in Foods of Animal Origin with Regard to Effect and Stability. Compr Rev Food Sci Food Saf 2018; 18:3-30. [PMID: 33337011 DOI: 10.1111/1541-4337.12402] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2018] [Revised: 09/28/2018] [Accepted: 09/29/2018] [Indexed: 01/09/2023]
Abstract
Amino acid (AA) sequences of 807 bioactive peptides from foods of animal origin were examined in order to correlate peptide structure with activity (antihypertensive, antioxidative, immunomodulatory, antimicrobial, hypolipidemic, antithrombotic, and opioid) and stability in vivo. Food sources, such as milk, meat, eggs, and marine products, show different frequencies of bioactive peptides exhibiting specific effects. There is a correlation of peptide structure and effect, depending on type and position of AA. Opioid peptides contain a high percentage of aromatic AA residues, while antimicrobial peptides show an excess of positively charged AAs. AA residue position is significant, with those in the first and penultimate positions having the biggest effects on peptide activity. Peptides that have activity in vivo contain a high percentage (67%) of proline residues, but the positions of proline in the sequence depend on the length of the peptide. We also discuss the influence of processing on activity of these peptides, as well as methods for predicting release from the source protein and activity of peptides.
Collapse
Affiliation(s)
- Elena Maestri
- Dept. of Chemistry, Life Sciences and Environmental Sustainability, Univ. of Parma, Parco Area delle Scienze 11/A, 43124, Parma, Italy.,Interdepartmental Centre for Food Safety, Technologies and Innovation for Agri-food (SITEIA.PARMA), Univ. of Parma, Parco Area delle Scienze, 43124, Parma, Italy
| | - Milica Pavlicevic
- Inst. for Food Technology and Biochemistry, Faculty of Agriculture, Univ. of Belgrade, Belgrade, Serbia
| | - Michela Montorsi
- Dept. of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open Univ., Via F. Daverio 7, 20122, Milan, Italy.,Consorzio Italbiotec, Via Fantoli, 16/15, 20138, Milano, Italy.,Inst. of Bioimaging and Molecular Physiology, National Council of Research (CNR), Via Fratelli Cervi 93, 20090, Segrate, Italy
| | - Nelson Marmiroli
- Dept. of Chemistry, Life Sciences and Environmental Sustainability, Univ. of Parma, Parco Area delle Scienze 11/A, 43124, Parma, Italy.,Interdepartmental Centre for Food Safety, Technologies and Innovation for Agri-food (SITEIA.PARMA), Univ. of Parma, Parco Area delle Scienze, 43124, Parma, Italy.,Consorzio Italbiotec, Via Fantoli, 16/15, 20138, Milano, Italy
| |
Collapse
|
5
|
Iwata Y, Harada A, Kubo C, Inoue T, Tabo M, Mishima M. Different players generate positive responses in two in vitro cytokine assay formats with aqueous and immobilized TGN1412 analog. Biochem Biophys Res Commun 2018; 502:91-97. [PMID: 29787754 DOI: 10.1016/j.bbrc.2018.05.125] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Accepted: 05/18/2018] [Indexed: 11/17/2022]
Abstract
To detect potential risk of severe cytokine release syndrome, in vitro assay formats with human cells have been developed. The two major testing platforms are a combination of whole blood with aqueous-phase test articles (whole blood cytokine assay, WBCA) and peripheral blood mononuclear cells with solid-phase articles (PBMC assay). Significant induction of cytokines was seen in both assays after treatment with a widely used control agent, TGN1412 or its analog CD28SA, but the WBCA cytokine profile differed from what was expected from clinical experience. In the WBCA, potential risk of CD28SA was detected by elevation of IL-8 whereas IL-2, a key cytokine after stimulation of CD28, was not induced in approximately 40% of donor samples. Therefore, further mechanistic understanding of the different responses in the in vitro assay was needed. In this study of donor samples treated with CD28SA, we compared the induction of cytokines and identified the cytokine-producing cells in the two assays. IL-2 was markedly elevated in all the donors in the PBMC assay but only in 1 of 3 donors in the WBCA. IL-8, the most sensitive biomarker in the WBCA, was produced by monocytes and granulocytes. T cells, the most relevant player in the PBMC assay with CD28SA, did not contribute to the positive response seen in two donors in the WBCA, which suggests that different players caused the positive cytokine responses to CD28SA in the two assays.
Collapse
Affiliation(s)
- Yoshika Iwata
- Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan
| | - Asako Harada
- Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan
| | - Chiyomi Kubo
- Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan
| | - Tomoaki Inoue
- Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan
| | - Mitsuyasu Tabo
- Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan
| | - Masayuki Mishima
- Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan.
| |
Collapse
|
6
|
Iwata Y, Harada A, Hara T, Kubo C, Inoue T, Tabo M, Ploix C, Manigold T, Hinton H, Mishima M. Is an in vitro whole blood cytokine assay useful to detect the potential risk of severe infusion reaction of monoclonal antibody pharmaceuticals? J Toxicol Sci 2017; 41:523-31. [PMID: 27432238 DOI: 10.2131/jts.41.523] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
After the life-threatening cytokine release syndrome (CRS) occurred in the clinical study of the anti-CD28 monoclonal antibody (mAb) TGN1412, in vitro cytokine release assays using human blood cells have been proposed for non-clinical evaluation of the potential risk of CRS. Two basic assay formats are frequently used: human peripheral blood mononuclear cells (PBMC) with immobilized mAbs, and whole blood with aqueous mAbs. However, the suitability of the whole blood cytokine assay (WBCA) has been questioned, because an unrealistically large sample size would be required to detect the potential risk of CRS induced by TGN1412, which has low sensitivity. We performed a WBCA using peripheral blood obtained from 68 healthy volunteers to compare two high risk mAbs, the TGN1412 analogue anti-CD28 superagonistic mAb (CD28SA) and the FcγR-mediated alemutuzumab, with a low risk mAb, panitumumab. Based on the cytokine measurements in this study, the sample size required to detect a statistically significant increase in cytokines with 90% power and 5% significance was determined to be n = 9 for CD28SA and n = 5 for alemtuzumab. The most sensitive marker was IL-8. The results suggest that WBCA is a practical test design that can warn of the potential risk of FcγR-mediated alemtuzumab and T-cell activating CD28SA but, because there was apparently a lower response to CD28SA, it cannot be used as a risk-ranking tool. WBCA is suggested to be a helpful tool for identifying potential FcγR-mediated hazards, but further mechanistic understanding of the response to CD28SA is necessary before applying it to T cell-stimulating mAbs.
Collapse
|
7
|
Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions. Cytokine 2016; 85:101-8. [PMID: 27309676 DOI: 10.1016/j.cyto.2016.06.006] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Accepted: 06/06/2016] [Indexed: 02/04/2023]
Abstract
In October 2013, the International Life Sciences Institute - Health and Environmental Sciences Institute Immunotoxicology Technical Committee (ILSI-HESI ITC) held a one-day workshop entitled, "Workshop on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions". The workshop brought together scientists from pharmaceutical, academic, health authority, and contract research organizations to discuss novel approaches and current challenges for the use of in vitro cytokine release assays (CRAs) for the identification of cytokine release syndrome (CRS) potential of novel monoclonal antibody (mAb) therapeutics. Topics presented encompassed a regulatory perspective on cytokine release and assessment, case studies regarding the translatability of preclinical cytokine data to the clinic, and the latest state of the science of CRAs, including comparisons between mAb therapeutics within one platform and across several assay platforms, a novel physiological assay platform, and assay optimization approaches such as determination of FcR expression profiles and use of statistical tests. The data and approaches presented confirmed that multiple CRA platforms are in use for identification of CRS potential and that the choice of a particular CRA platform is highly dependent on the availability of resources for individual laboratories (e.g. positive and negative controls, number of human blood donors), the assay through-put required, and the mechanism-of-action of the therapeutic candidate to be tested. Workshop participants agreed that more data on the predictive performance of CRA platforms is needed, and current efforts to compare in vitro assay results with clinical cytokine assessments were discussed. In summary, many laboratories continue to focus research efforts on the improvement of the translatability of current CRA platforms as well explore novel approaches which may lead to more accurate, and potentially patient-specific, CRS prediction in the future.
Collapse
|
8
|
Vessillier S, Eastwood D, Fox B, Sathish J, Sethu S, Dougall T, Thorpe SJ, Thorpe R, Stebbings R. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm. J Immunol Methods 2015; 424:43-52. [PMID: 25960173 PMCID: PMC4768082 DOI: 10.1016/j.jim.2015.04.020] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Revised: 04/29/2015] [Accepted: 04/29/2015] [Indexed: 12/29/2022]
Abstract
The therapeutic monoclonal antibody (mAb) TGN1412 (anti-CD28 superagonist) caused near-fatal cytokine release syndrome (CRS) in all six volunteers during a phase-I clinical trial. Several cytokine release assays (CRAs) with reported predictivity for TGN1412-induced CRS have since been developed for the preclinical safety testing of new therapeutic mAbs. The whole blood (WB) CRA is the most widely used, but its sensitivity for TGN1412-like cytokine release was recently criticized. In a comparative study, using group size required for 90% power with 5% significance as a measure of sensitivity, we found that WB and 10% (v/v) WB CRAs were the least sensitive for TGN1412 as these required the largest group sizes (n = 52 and 79, respectively). In contrast, the peripheral blood mononuclear cell (PBMC) solid phase (SP) CRA was the most sensitive for TGN1412 as it required the smallest group size (n = 4). Similarly, the PBMC SP CRA was more sensitive than the WB CRA for muromonab-CD3 (anti-CD3) which stimulates TGN1412-like cytokine release (n = 4 and 4519, respectively). Conversely, the WB CRA was far more sensitive than the PBMC SP CRA for alemtuzumab (anti-CD52) which stimulates FcγRI-mediated cytokine release (n = 8 and 180, respectively). Investigation of potential factors contributing to the different sensitivities revealed that removal of red blood cells (RBCs) from WB permitted PBMC-like TGN1412 responses in a SP CRA, which in turn could be inhibited by the addition of the RBC membrane protein glycophorin A (GYPA); this observation likely underlies, at least in part, the poor sensitivity of WB CRA for TGN1412. The use of PBMC SP CRA for the detection of TGN1412-like cytokine release is recommended in conjunction with adequately powered group sizes for dependable preclinical safety testing of new therapeutic mAbs.
Collapse
Affiliation(s)
- S Vessillier
- National Institute for Biological Standards and Control, Biotherapeutics Group, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom.
| | - D Eastwood
- National Institute for Biological Standards and Control, Biotherapeutics Group, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| | - B Fox
- National Institute for Biological Standards and Control, Biotherapeutics Group, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| | - J Sathish
- MRC Centre for Drug Safety Science, Department of Molecular & Clinical Pharmacology, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom
| | - S Sethu
- MRC Centre for Drug Safety Science, Department of Molecular & Clinical Pharmacology, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom
| | - T Dougall
- National Institute for Biological Standards and Control, Biotherapeutics Group, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| | - S J Thorpe
- National Institute for Biological Standards and Control, Biotherapeutics Group, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| | - R Thorpe
- National Institute for Biological Standards and Control, Biotherapeutics Group, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| | - R Stebbings
- National Institute for Biological Standards and Control, Biotherapeutics Group, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom; MRC Centre for Drug Safety Science, Department of Molecular & Clinical Pharmacology, University of Liverpool, Sherrington Buildings, Ashton Street, Liverpool L69 3GE, United Kingdom; Medimmune, Aaron Klug Building, Granta Park, Cambridge CB21 6GH, United Kingdom.
| |
Collapse
|
9
|
Reed DM, Paschalaki KE, Starke RD, Mohamed NA, Sharp G, Fox B, Eastwood D, Bristow A, Ball C, Vessillier S, Hansel TT, Thorpe SJ, Randi AM, Stebbings R, Mitchell JA. An autologous endothelial cell:peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics. FASEB J 2015; 29:2595-602. [PMID: 25746794 DOI: 10.1096/fj.14-268144] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Accepted: 02/13/2015] [Indexed: 11/11/2022]
Abstract
There is an urgent unmet need for human tissue bioassays to predict cytokine storm responses to biologics. Current bioassays that detect cytokine storm responses in vitro rely on endothelial cells, usually from umbilical veins or cell lines, cocultured with freshly isolated peripheral blood mononuclear cells (PBMCs) from healthy adult volunteers. These assays therefore comprise cells from 2 separate donors and carry the disadvantage of mismatched tissues and lack the advantage of personalized medicine. Current assays also do not fully delineate mild (such as Campath) and severe (such as TGN1412) cytokine storm-inducing drugs. Here, we report a novel bioassay where endothelial cells grown from stem cells in the peripheral blood (blood outgrowth endothelial cells) and PBMCs from the same donor can be used to create an autologous coculture bioassay that responds by releasing a plethora of cytokines to authentic TGN1412 but only modestly to Campath and not to control antibodies such as Herceptin, Avastin, and Arzerra. This assay performed better than the traditional mixed donor assay in terms of cytokine release to TGN1412 and, thus, we suggest provides significant advancement and a definitive system by which biologics can be tested and paves the way for personalized medicine.
Collapse
Affiliation(s)
- Daniel M Reed
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Koralia E Paschalaki
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Richard D Starke
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Nura A Mohamed
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Giles Sharp
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Bernard Fox
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - David Eastwood
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Adrian Bristow
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Christina Ball
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Sandrine Vessillier
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Trevor T Hansel
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Susan J Thorpe
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Anna M Randi
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Richard Stebbings
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| | - Jane A Mitchell
- *Department of Cardiothoracic Pharmacology, Vascular Biology Section, National Heart and Lung Institute, and Vascular Sciences, National Heart and Lung Institute, Hammersmith Hospital, Imperial College London, London, United Kingdom; Qatar Foundation Research and Development Division, Doha, Qatar; National Institute for Biological Standards and Control, Potters Bar, United Kingdom; Imperial Clinical Respiratory Research Unit, St. Mary's Hospital, London, United Kingdom; and Medimmune, Cambridge, United Kingdom
| |
Collapse
|
10
|
Cryopreservation of human monocytes for pharmacopeial monocyte activation test. J Immunol Methods 2014; 405:181-91. [DOI: 10.1016/j.jim.2014.01.005] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2013] [Revised: 12/17/2013] [Accepted: 01/10/2014] [Indexed: 12/24/2022]
|
11
|
Finco D, Grimaldi C, Fort M, Walker M, Kiessling A, Wolf B, Salcedo T, Faggioni R, Schneider A, Ibraghimov A, Scesney S, Serna D, Prell R, Stebbings R, Narayanan PK. Cytokine release assays: current practices and future directions. Cytokine 2014; 66:143-55. [PMID: 24412476 DOI: 10.1016/j.cyto.2013.12.009] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2013] [Revised: 11/18/2013] [Accepted: 12/09/2013] [Indexed: 12/18/2022]
Abstract
As a result of the CD28 superagonist biotherapeutic monoclonal antibody (TGN 1412) "cytokine storm" incident, cytokine release assays (CRA) have become hazard identification and prospective risk assessment tools for screening novel biotherapeutics directed against targets having a potential risk for eliciting adverse pro-inflammatory clinical infusion reactions. Different laboratories may have different strategies, assay formats, and approaches to the reporting, interpretation, and use of data for either decision making or risk assessment. Additionally, many independent contract research organizations (CROs), academic and government laboratories are involved in some aspect of CRA work. As a result, while some pharmaceutical companies are providing CRA data as part of the regulatory submissions when necessary, technical and regulatory practices are still evolving to provide data predictive of cytokine release in humans and that are relevant to safety. This manuscript provides an overview of different approaches employed by the pharmaceutical industry and CROs, for the use and application of CRA based upon a survey and post survey follow up conducted by ILSI-Health and Environmental Sciences Institute (HESI) Immunotoxicology Committee CRA Working Group. Also discussed is ongoing research in the academic sector, the regulatory environment, current limitations of the assays, and future directions and recommendations for cytokine release assays.
Collapse
Affiliation(s)
- D Finco
- Pfizer Worldwide Research and Development, Groton, CT, USA.
| | - C Grimaldi
- Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
| | - M Fort
- Discovery Toxicology, Amgen Inc., Seattle, WA, USA
| | - M Walker
- Janssen Research and Development, Spring House, PA, USA
| | | | - B Wolf
- Novartis Pharma AG, Basel, Switzerland
| | - T Salcedo
- Immunotoxicology, Bristol-Myers Squibb, New Brunswick, NJ, USA
| | - R Faggioni
- Clinical Pharmacology & DMPK, MedImmune, LLC, Hayward, CA, USA
| | - A Schneider
- Clinical Pharmacology & DMPK, MedImmune, LLC, Hayward, CA, USA
| | | | - S Scesney
- AbbVie Bioresearch Center, Worcester, MA, USA
| | - D Serna
- AbbVie Bioresearch Center, Worcester, MA, USA
| | - R Prell
- Genentech Inc., South San Francisco, USA
| | - R Stebbings
- National Institute for Biological Standards & Control, Potters Bar, UK
| | | |
Collapse
|